Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review
Cells · 24.04.2024 · 13 (9) · 743
DOI: 10.3390/cells13090743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 24.04.2024. Verfasst von James Perera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Biomarkers, Synovial Membrane, Phenotype. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research Barts Biomedical Research Centre, Experimental Arthritis Treatment Centre.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disorder which can lead to long-term joint damage and significantly reduced quality of life if not promptly diagnosed and adequately treated. Despite significant advances in treatment, about 40% of patients with RA do not respond to individual pharmacological agents and up to 20% do not respond to any of the available medications. To address this large unmet clinical need, several recent studies have focussed on an in-depth histological and molecular characterisation of the synovial tissue to drive the application of precision medicine to RA. Currently, RA patients are clinically divided into “seropositive” or “seronegative” RA, depending on the presence of routinely checked antibodies. Recent work has suggested that over the last two decades, long-term outcomes have improved significantly in seropositive RA but not in seronegative RA. Here, we present up-to-date differences in epidemiology, clinical features, and serological biomarkers in seronegative versus seropositive RA and discuss how histological and molecular synovial signatures, revealed by recent large synovial biopsy-based clinical trials, may be exploited to refine the classification of RA patients, especially in the seronegative group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London EC1M 6BQ, UK.
- Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, 28100 Novara, Italy.
- Department of Biomedical Sciences, Humanitas University & IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
ORCID-Profile: James Perera, Alessandra Nerviani, Costantino Pitzalis
Förderung
- National Institute for Health Research Barts Biomedical Research Centre
- Experimental Arthritis Treatment Centre
Zitieren
APA
Perera, J., Delrosso, C. A., Nerviani, A., & Pitzalis, C. (2024). Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells, 13(9), 743. https://doi.org/10.3390/cells13090743
Vancouver
Perera J, Delrosso CA, Nerviani A, Pitzalis C. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13(9):743. doi:10.3390/cells13090743
BibTeX
@article{Perera2024,
author = {Perera, James and Delrosso, Chiara Aurora and Nerviani, Alessandra and Pitzalis, Costantino},
title = {Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review},
journal = {Cells},
year = {2024},
volume = {13},
number = {9},
pages = {743},
doi = {10.3390/cells13090743}
}
EUVIMED